1. Development of a chemiluminescence assay for tissue plasminogen activator inhibitor complex and its applicability to gastric cancer.
- Author
-
Ji Y, Qin Y, Tan Q, Qiu Y, Han S, and Qi X
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Antithrombin III metabolism, Antithrombin III analysis, Thrombomodulin blood, Fibrin Fibrinogen Degradation Products analysis, Fibrin Fibrinogen Degradation Products metabolism, alpha-2-Antiplasmin metabolism, alpha-2-Antiplasmin analysis, Adult, Fibrinolysin metabolism, Fibrinolysin analysis, Venous Thromboembolism diagnosis, Venous Thromboembolism blood, Peptide Hydrolases, Stomach Neoplasms diagnosis, Luminescent Measurements methods
- Abstract
Background: Venous thromboembolism (VTE), is a noteworthy complication in individuals with gastric cancer, but the current diagnosis and treatment methods lack accuracy. In this study, we developed a t-PAIC chemiluminescence kit and employed chemiluminescence to detect the tissue plasminogen activator inhibitor complex (t-PAIC), thrombin-antithrombin III complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC) and thrombomodulin (TM), combined with D-dimer and fibrin degradation products (FDP), to investigate their diagnostic potential for venous thrombosis in gastric cancer patients. The study assessed variations in six indicators among gastric cancer patients at different stages., Results: The t-PAIC reagent showed LOD is 1.2 ng/mL and a linear factor R greater than 0.99. The reagents demonstrated accurate results, with all accuracy deviations being within 5%. The intra-batch and inter-batch CVs for the t-PAIC reagent were both within 8%. The correlation coefficient R between this method and Sysmex was 0.979. Gastric cancer patients exhibited elevated levels of TAT, PIC, TM, D-D, FDP compared to the healthy population, while no significant difference was observed in t-PAIC. In the staging of gastric cancer, patients in III-IV stages exhibit higher levels of the six markers compared to those in I-II stages. The ROC curve indicates an enhancement in sensitivity and specificity of the combined diagnosis of four or six indicators., Conclusion: Our chemiluminescence assay performs comparably to Sysmex's method and at a reduced cost. The use of multiple markers, including t-PAIC, TM, TAT, PIC, D-D, and FDP, is superior to the use of single markers for diagnosing VTE in patients with malignant tumors. Gastric cancer patients should be screened for the six markers to facilitate proactive prophylaxis, determine the most appropriate treatment timing, ameliorate their prognosis, decrease the occurrence of venous thrombosis and mortality, and extend their survival., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF